Wellysis

Wellysis is a digital healthcare company that develops wearable biosensing devices and AI-powered analytics for cardiac monitoring. Spun off from Samsung SDS in 2019, the company is headquartered in Seoul, South Korea, with a U.S. subsidiary, Wellysis USA Inc., established in Houston, Texas, in 2023. The company was founded by its current CEO, Young Juhn, who has over 25 years of experience in the healthcare sector, including leadership roles at Johnson & Johnson, Kaiser Permanente, and Samsung SDS, where he led healthcare innovation projects before launching Wellysis.

The company's flagship product is the S-Patch, a lightweight, water-resistant, and reusable single-lead ECG monitoring patch designed for continuous cardiac data collection. Models like the S-Patch Ex and S-Patch ExL are designed for extended monitoring periods of up to 14 days on a single battery charge. The devices weigh between 8.5g and 11g and are designed to be unobtrusive for patients during daily activities. The S-Patch system includes the wearable device, a mobile app for patients to view live ECG data and log symptoms, and a cloud-based web portal for physicians. Data collected by the patch is analyzed by an AI-powered platform, CardioAI, to detect arrhythmias and provide clinicians with detailed reports to support diagnosis.

Wellysis operates on a business-to-business model, serving hospitals, clinics, and clinical research organizations (CROs). Its revenue is generated through the sale of its S-Patch devices and partnerships for its ECG analysis services. In the U.S., the company has secured insurance reimbursement for its monitoring services, including Holter monitoring and Mobile Cardiac Telemetry (MCT), from public insurers like Medicare and Medicaid, as well as private insurers. Wellysis has established partnerships with Independent Diagnostic Testing Facilities (IDTFs) to distribute its products and has an exclusive agreement with HeartcoR Solutions to use the S-Patch in clinical trials. The company is expanding globally, with a presence in 14 countries, and has formed strategic partnerships to enter the U.S. and Indian markets.

Since its inception, Wellysis has raised approximately $30 million in funding. A Series A round in May 2022 brought in $4 million, and a pre-IPO round in early 2026 raised $13.5 million. The company has received FDA clearance for its S-Patch Ex and S-Patch ExL devices and is planning a KOSDAQ listing between late 2026 and early 2027. Wellysis is also developing BioArmour, a multi-biosignal monitoring solution for non-medical applications in sports, public safety, and defense sectors.

Keywords: cardiac monitoring, wearable ECG, arrhythmia detection, digital healthcare, S-Patch, AI diagnostics, remote patient monitoring, electrocardiogram, Holter monitor, cardiovascular disease, medical device, biosensor, Mobile Cardiac Telemetry (MCT), clinical trials, healthcare data, AI algorithm, heart rate monitoring, real-time data, cloud platform, FDA clearance, Samsung spin-off, patient care, diagnostic software, biometric data, preventative healthcare, CardioAI, BioArmour, arrhythmia screening, ambulatory cardiac monitoring, biosensing